The study and its comparison
The randomized research included 1,273 participants. Its population was infants born before twenty-nine weeks of gestation. The comparison used enteral dha emulsion 60 mg/kg daily versus dha-free soy emulsion, with observation over until thirty-six weeks postmenstrual age or assessment. [1]
Among survivors assessed, physiological bronchopulmonary dysplasia was reported in 49.1% with DHA and 43.9% with control, using the study analysis. The adjusted relative risk was 1.13. Death alone did not differ significantly. [1]
What the finding establishes
Physiological and clinical definitions produced different statistical results, so the endpoint definition matters. The findings concern a specific neonatal regimen and cannot be applied to ordinary adult dietary intake. Australian NHMRC and others funded the trial; complete conflicts were not established from the abstract. [1]
A hypothetical distinction
Imagine a nutrient is biologically important but a particular added dose worsens a trial endpoint. Essentiality does not guarantee benefit from extra supplementation.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.